Boston Scientific Corporation (NYSE:BSX) will be treading cautiously with its Vessix renal denervation platform in the U.S. after Medtronic‘s (NYSE:MDT) SYMPLICITY HTN-3 trial failed to meet its efficacy endpoint last month. Boston Scientific Corporation (NYSE:BSX) stock opened at $13.28 in last session, and closed at $13.10, while the day range of stock is $12.98 – $13.34. The stock showed a negative weekly performance of -0.30%.
Opko Health Inc (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 15,000 shares of the company’s stock in a transaction dated Thursday, February 27th. Opko Health Inc. (NYSE:OPK) stock opened at $9.46, in last session and closed at $9.52, by gaining 1.82%. The 52 week range of is $6.14 – $12.95. Company’s market capitalization is $3.88 billion.
MassDevice.com has reported that Medtronic Inc. (NYSE:MDT) is receiving over $1 million in repayments from a New Zealand doctor after forensics revealed the surgeon faked invoices to avoid debt. Medtronic, Inc. (NYSE:MDT) stock advanced 1.65% and finished the last session at $59.26. The EPS of the stock remained 3.74. Company’s market capitalization is $59.16 billion.
M&A: Kalamazoo-based medical device maker Stryker Corp. (NYSE:SYK) announced last month that it had signed definitive agreements for two acquisitions. Stryker Corp. (NYSE:SYK) said it planned to acquire privately held device manufacturer Berchtold Holding AG for $172 million and Sunnyvale, Calif.-based Pivot Medical Inc. for an undisclosed amount in an all-cash transaction. Stryker Corporation (NYSE:SYK) stock opened the session at $81.17, and closed the session at $80.24. The 52 week range of the SYK stock remained $63.18 – $83.86 and the day range was $79.84 – $81.52.
Leave a Reply